367 related articles for article (PubMed ID: 18693160)
1. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
Aoyama Y; Nagasawa C; Nagai M; Kitajima Y
Eur J Dermatol; 2008; 18(5):557-60. PubMed ID: 18693160
[TBL] [Abstract][Full Text] [Related]
2. An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg.
Habib N; Bystryn JC
Eur J Dermatol; 2009; 19(2):190; author reply 191. PubMed ID: 19106059
[No Abstract] [Full Text] [Related]
3. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
[TBL] [Abstract][Full Text] [Related]
4. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy.
Aoyama Y; Moriya C; Kamiya K; Nagai M; Rubenstein D; Iwatsuki K; Kitajima Y
Eur J Dermatol; 2011; 21(1):58-61. PubMed ID: 21233063
[TBL] [Abstract][Full Text] [Related]
5. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
Bystryn JC; Jiao D
Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
[TBL] [Abstract][Full Text] [Related]
6. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
[TBL] [Abstract][Full Text] [Related]
7. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
10. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission.
Kwon EJ; Yamagami J; Nishikawa T; Amagai M
J Eur Acad Dermatol Venereol; 2008 Sep; 22(9):1070-5. PubMed ID: 18410336
[TBL] [Abstract][Full Text] [Related]
11. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
Sami N; Bhol KC; Ahmed RA
Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
Czernik A; Beutner EH; Bystryn JC
J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
[TBL] [Abstract][Full Text] [Related]
14. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus.
Ohyama M; Amagai M; Hashimoto T; Nousari HC; Anhalt GJ; Nishikawa T
J Am Acad Dermatol; 2001 Apr; 44(4):593-8. PubMed ID: 11260531
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of long-term history showing favorable outcome.
Frost N; Messer G; Fierlbeck G; Risler T; Lytton SD
Ann N Y Acad Sci; 2005 Jun; 1051():591-6. PubMed ID: 16126999
[TBL] [Abstract][Full Text] [Related]
16. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
Turner MS; Sutton D; Sauder DN
J Am Acad Dermatol; 2000 Dec; 43(6):1058-64. PubMed ID: 11100023
[TBL] [Abstract][Full Text] [Related]
17. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.
Mimouni D; Blank M; Ashkenazi L; Milner Y; Frusic-Zlotkin M; Anhalt GJ; David M; Shoenfeld Y
Clin Exp Immunol; 2005 Dec; 142(3):426-32. PubMed ID: 16297153
[TBL] [Abstract][Full Text] [Related]
20. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA
Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
